首页> 外文期刊>Western Journal of Emergency Medicine >Anticoagulation Drug Therapy: A Review
【24h】

Anticoagulation Drug Therapy: A Review

机译:抗凝药物治疗:综述

获取原文
           

摘要

Historically, most patients who required parenteral anticoagulation received heparin, whereas those patients requiring oral anticoagulation received warfarin. Due to the narrow therapeutic index and need for frequent laboratory monitoring associated with warfarin, there has been a desire to develop newer, more effective anticoagulants. Consequently, in recent years many novel anticoagulants have been developed. The emergency physician may institute anticoagulation therapy in the short term (e.g. heparin) for a patient being admitted, or may start a novel anticoagulation for a patient being discharged. Similarly, a patient on a novel anticoagulant may present to the emergency department due to a hemorrhagic complication. Consequently, the emergency physician should be familiar with the newer and older anticoagulants. This review emphasizes the indication, mechanism of action, adverse effects, and potential reversal strategies for various anticoagulants that the emergency physician will likely encounter. [West J Emerg Med. 2015;16(1):–0.].
机译:从历史上看,大多数需要肠胃外抗凝治疗的患者都接受肝素,而那些需要口服抗凝治疗的患者则接受华法林。由于狭窄的治疗指数以及与华法令有关的经常性实验室监测的需求,人们希望开发出更新,更有效的抗凝剂。因此,近年来,已经开发了许多新型抗凝剂。急诊医师可以在短期内对入院患者进行抗凝治疗(例如肝素),也可以对出院患者进行新型抗凝治疗。同样,由于出血并发症,使用新型抗凝剂的患者可能会出现在急诊科。因此,急诊医师应熟悉较新和较旧的抗凝剂。这篇综述着重介绍了急诊医师可能会遇到的各种抗凝剂的适应症,作用机理,不良反应和潜在的逆转策略。 [西急救医学杂志。 2015; 16(1):– 0。]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号